Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet-fed streptozotocin-treated diabetic rats

Noha M Gamil; Mai A Abd El Fattah; Maha A E Ahmed; Yousreya A Maklad; Amina A Gamal El Din; Nihad I Eid

doi:10.1002/jbt.22451

Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet-fed streptozotocin-treated diabetic rats

J Biochem Mol Toxicol. 2020 Apr;34(4):e22451. doi: 10.1002/jbt.22451. Epub 2020 Jan 23.

Authors

Noha M Gamil¹, Mai A Abd El Fattah², Maha A E Ahmed¹, Yousreya A Maklad³, Amina A Gamal El Din⁴, Nihad I Eid²

Affiliations

¹ Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, 6th of October City, Egypt.
² Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
³ Medicinal and Pharmaceutical Chemistry Department (Pharmacology Group), Pharmaceutical and Drug Industries Research Division, National Research Centre, Giza, Egypt.
⁴ Medical Research Division, Pathology Department, National Research Centre, Giza, Egypt.

PMID: 31975531
DOI: 10.1002/jbt.22451

Abstract

Dapagliflozin (DAPA) is used for treating type 2 diabetes, whereas lansoprazole (LPZ) is used as a traditional antiulcer drug. The present study investigated the possible antidiabetic effects of LPZ on fortified diet-fed streptozotocin (FDF/STZ)-induced insulin-resistant diabetic rats. On the basis of the current results, it can be concluded that LPZ could be used as an add-on drug along with the conventional treatment for T2D as it showed beneficial effects in the current experimental model of insulin resistance.

Keywords: Glut-2 expression; dapagliflozin; fortified diet; insulin resistance; lansoprazole.

MeSH terms

Animals
Benzhydryl Compounds / therapeutic use*
Blood Glucose / analysis
Blood Glucose / drug effects
Body Weight / drug effects
Cholesterol / blood
Cholesterol / metabolism
Diabetes Mellitus, Experimental / chemically induced
Diabetes Mellitus, Experimental / drug therapy*
Diabetes Mellitus, Experimental / etiology
Diabetes Mellitus, Experimental / metabolism
Disease Models, Animal
Drug Synergism
Drug Therapy, Combination
Food, Fortified / adverse effects
Glucose Transporter Type 2 / genetics
Glucose Transporter Type 2 / metabolism
Glucosides / therapeutic use*
Hypoglycemic Agents / therapeutic use*
Inflammation Mediators / blood
Inflammation Mediators / metabolism
Insulin Resistance*
Lansoprazole / therapeutic use*
Male
Oxidative Stress / drug effects
PPAR gamma / blood
Pancreas / metabolism
Pancreas / pathology
Random Allocation
Rats
Rats, Wistar
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*

Substances

Benzhydryl Compounds
Blood Glucose
Glucose Transporter Type 2
Glucosides
Hypoglycemic Agents
Inflammation Mediators
PPAR gamma
PPAR gamma, rat
Slc2a2 protein, rat
Sodium-Glucose Transporter 2 Inhibitors
Lansoprazole
dapagliflozin
Cholesterol